Maze Therapeutics, Inc. (MAZE)

US — Healthcare Sector
Peers: IMTX  TSHA  NUVB  SION  TRML  ARDX  ORIC  ELVN  NBTX  WVE 

Automate Your Wheel Strategy on MAZE

With Tiblio's Option Bot, you can configure your own wheel strategy including MAZE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MAZE
  • Rev/Share 0.057
  • Book/Share 5.9802
  • PB 4.8928
  • Debt/Equity 0.0954
  • CurrentRatio 13.6256
  • ROIC -0.4344

 

  • MktCap 1283076866.0
  • FreeCF/Share -2.4315
  • PFCF -12.0335
  • PE -10.6218
  • Debt/Assets 0.0824
  • DivYield 0
  • ROE 11.6686

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MAZE BTIG Research -- Buy -- $30 Sept. 2, 2025
Initiation MAZE H.C. Wainwright -- Buy -- $34 July 23, 2025
Initiation MAZE Wedbush -- Outperform -- $17 July 8, 2025

News

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry
MAZE
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry. Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry.

Read More
image for news National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

About Maze Therapeutics, Inc. (MAZE)

  • IPO Date 2025-01-31
  • Website https://www.mazetx.com
  • Industry Biotechnology
  • CEO Jason V. Coloma M.P.H.,
  • Employees 125
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.